论文部分内容阅读
目的:分析β2-受体激动剂联合吸入糖皮质激素治疗持续性哮喘的临床疗效。方法:选取我院2013年4月到2014年4月间收治的92例持续性哮喘患者,根据患者治疗方法不同分为两组,其中观察组(46例)行氟替卡松+福特莫罗治疗,对照组(46例)单纯行氟替卡松治疗,对比两组患者治疗前后气道反应指标情况。结果:两组患者治疗后PC20-FEV1、PD20-FEV1均显著改善(p<0.05),但观察组患者改善情况优于对照组(p<0.05)。结论:β2-受体激动剂联合吸入糖皮质激素在改善持续性哮喘患者症状上具有较高疗效,且患者不良反应率显著低于单纯性吸入糖皮质激素患者。
Objective: To analyze the clinical efficacy of β2-agonist combined with inhaled corticosteroids in the treatment of persistent asthma. Methods: Ninety-two patients with persistent asthma who were admitted to our hospital from April 2013 to April 2014 were divided into two groups according to the different treatment methods. The observation group (46 patients) received fluticasone + Group (n = 46) were treated with fluticasone alone. The airway response indexes before and after treatment were compared between the two groups. Results: The PC20-FEV1 and PD20-FEV1 in both groups were significantly improved after treatment (p <0.05), but the improvement in the observation group was better than that in the control group (p <0.05). CONCLUSION: The combination of β2-agonist and inhaled glucocorticoid has a higher efficacy in improving the symptoms of patients with persistent asthma, and the adverse reaction rate of patients with AD was significantly lower than that of patients with simple inhaled glucocorticoid.